Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

Clinical trial NCT05924100 · RECRUITING

Trial details

NCT number: NCT05924100
Sponsor: Associazione Qol-one
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndromes Del(5Q)Anemia Transfusion-dependent Anemia

Start date: 2022-11-03
Primary completion: 2024-12-03
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.